Resumo

COLONIA, Ana; RIVERA, Juliana; OROZCO, Juan  e  MARIN, Daniel. HER-2: A molecular marker used in the diagnosis, forecasting and treatment of breast cancer. Revista médica Risaralda [online]. 2015, vol.21, n.1, pp.31-37. ISSN 0122-0667.

Currently, the specific cause of breast cancer is unknown, but have been identified a variety of genes involved in its development. One of these is the HER2, whose overexpression, and hence their receptors, is present in about 20 to 30% of breast cancers as a result of amplification of the chromosomal region 17q12-21, and is associated with aggressive subtypes and with low survival. Receptor expression provides critical information for the diagnosis, prognosis and treatment in patients with breast cancer. Accurate diagnosis of HER2 status is essential because of its relationship to treatment with Trastuzumab and other drugs that improve survival in these patients For diagnosis have been designed several techniques, which determine HER2 status in tumor, such as immunohistochemistry (IHC) and in situ hybridization (ISH). Some of the results obtained by IHC are classified as inconclusive, so the IHC has emerged as a primary screening test followed by an ISH confirmatory test

Palavras-chave : Genes; erbB-2; Breast Neoplasms; Molecular Biology; In Situ Hybridization; Fluorescence.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )